Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price was down 6.3% during trading on Wednesday . The company traded as low as $1.45 and last traded at $1.50. Approximately 9,544 shares traded hands during trading, a decline of 61% from the average daily volume of 24,633 shares. The stock had previously closed at $1.60.
Humacyte Price Performance
The business has a fifty day simple moving average of $1.42 and a 200-day simple moving average of $0.87.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Read More
- Five stocks we like better than Humacyte
- What is a Dividend King?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Upcoming IPO Stock Lockup Period, Explained
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Conference Calls and Individual Investors
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
